Pharming (PHAR) EBT Margin (2020 - 2026)
Pharming's (PHAR) quarterly EBT Margin came in at 16.08% in Q2 2026, up 1387.0% YoY from 1.08% in Q2 2025, and up 100.0% on a QoQ basis from 20316921335597.06% in Q1 2026.
Pharming (PHAR) EBT Margin (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of EBT Margin data on file, last reported at 16.08% in Q2 2026.
- Quarterly EBT Margin rose 1387.0% year-over-year to 16.08% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 10.24% (up 3946.0% YoY) and the FY2025 annual result came in at 3.42%, up 627.0% from the prior year.
- EBT Margin grew to 16.08% in Q2 2026, from 20316921335597.06% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2024064.17% in Q3 2024 to a low of 20316921335597.06% in Q1 2026.
- A 5-year average of 1128718792064.15% and a median of 1.1% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin jumped 1064053621 bps — and 2026, when it sank 2000000000 bps.
- Tracing PHAR's EBT Margin over 5 years: stood at 21.92% in 2022, then tumbled by 67485255 bps to 14793103.45% in 2023, then surged by 72 bps to 4152567.24% in 2024, then jumped by 100 bps to 0.0% in 2025, then soared by 356669487 bps to 16.08% in 2026.
- The last three EBT Margin figures came in at 16.08% (Q2 2026), 20316921335597.06% (Q1 2026), and 0.0% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 16.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.08% |
| Mar 31, 2026 | -20,316,921,335,597.06% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 26.82% |
| Jun 30, 2025 | 2.21% |
| Mar 31, 2025 | -20.39% |
| Dec 31, 2024 | -4,152,567.24% |
| Sep 30, 2024 | 2,024,064.17% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | -29.35% |
| Dec 31, 2023 | -14,793,103.45% |
| Sep 30, 2023 | 4.96% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | -32.12% |
| Dec 31, 2022 | 21.92% |
| Sep 30, 2022 | 17.16% |
| Jun 30, 2022 | 35.53% |
| Mar 31, 2022 | 6.01% |
| Dec 31, 2021 | -9.18% |
| Sep 30, 2021 | -37.16% |